FLT3 and acute myeloid leukemia: However, there is still scarce data on the efficacy of CPX‐351 in NPM1 or FLT3‐ITD mutated AML or in patients with low‐risk AML, according to European Leukemia Net (ELN 2017‐2022) classification, as those subgroups are quite rare among s‐AML, therefore requiring a large patients' cohort in order to draw any conclusion.